In another research [75], an EV protein component, complement factor H (CFH), isolated from the plasma of lung adenocarcinoma patients and highly metastatic hepatocellular carcinoma (HCC), was also shown to be active in tumor cell-derived EVs and protect them from complement lysis and phagocytosis. This evidence concerns the gene CFH and hepatocellular carcinoma.